指南与共识骨软组织肉瘤与黑色素瘤

欧洲癌症研究与治疗组织关于蕈样肉芽肿/Sézary综合征治疗的共识建议——2017年更新

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
指南 / 共识 · Eur J Cancer · 2017-03-31

欧洲癌症研究与治疗组织-皮肤淋巴瘤工作组(EORTC-CLTF)更新了2006年蕈样肉芽肿(MF)/Sézary综合征(SS)的共识治疗建议,按疾病分期列出推荐方案并尽可能区分一线与二线,附牛津循证医学中心(OCEBM)证据级别。早期MF仍以皮肤导向治疗为最合适选择,多数患者预期寿命正常;晚期预后仍差,仅高度选择患者可通过异基因干细胞移植(alloSCT)获得生存延长。

要点

  • 早期MF最合适的治疗仍是皮肤导向治疗,多数患者预期寿命正常。
  • 晚期MF/SS预后仍差,仅高度选择患者可通过alloSCT获得生存延长。
  • 推荐按疾病分期呈现,尽可能区分一线与二线并附OCEBM证据级别。

核心结论

  • 早期MF最合适的治疗选择仍是皮肤导向治疗,多数患者预期寿命正常。
  • 晚期疾病预后仍差,仅高度选择的部分患者可通过alloSCT获得生存延长。
  • 亟需在对照临床试验中研发和验证基于对MF/SS分子病理认识不断深入的治疗选择。

研究设计与样本

  • 欧洲癌症研究与治疗组织-皮肤淋巴瘤工作组(EORTC-CLTF)发布的共识建议更新。
  • 共识通过作者间一系列连续书面咨询和一轮讨论形成。
  • 推荐按疾病分期呈现,尽可能分为一线与二线选项,并附牛津循证医学中心(OCEBM)证据级别。

主要发现

  • 自2006年版发布以来,MF/SS的病理生理与流行病学认识有所进展,分期系统已修订,新的结局数据已发表,新的治疗选择已引入。
  • 支持MF/SS治疗决策的对照研究数量仍然有限,治疗常由机构经验和可获得性决定。

关键数值与推荐

  • 推荐治疗选项按疾病分期呈现,尽可能分为一线与二线,并附OCEBM证据级别。
  • 早期MF最合适的治疗选择为皮肤导向治疗。

临床怎么用

  • 按疾病分期选择治疗方案,尽可能区分一线与二线选项并参考所附OCEBM证据级别。
  • 原文指出支持治疗决策的对照研究数量仍有限,治疗常由机构经验和可获得性决定。

局限性

  • 支持MF/SS治疗决策的对照研究数量仍然有限。
  • 治疗常由机构经验和可获得性决定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS has advanced, the staging system has been revised, new outcome data have been published and novel treatment options have been introduced. The purpose of the present document is to update the original recommendations bearing in mind that there are still only a limited number of controlled studies to support treatment decisions for MF/SS and that often treatment is determined by institutional experience and availability. This consensus on treatment recommendations was established among the authors through a series of consecutive consultations in writing and a round of discussion. Recommended treatment options are presented according to disease stage, whenever possible categorised into first- and second-line options and supported with levels of evidence as devised by the Oxford Centre for Evidence-Based Medicine (OCEBM). Skin-directed therapies are still the most appropriate option for early-stage MF, and most patients can look forward to a normal life expectancy. For patients with advanced disease, prognosis is still grim, and only for a highly selected subset of patients, prolonged survival can be achieved with allogeneic stem cell transplantation (alloSCT). There is a high need for the development and investigation in controlled clinical trials of treatment options that are based on our increasing understanding of the molecular pathology of MF/SS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017. PMID: 28365528. doi:10.1016/j.ejca.2017.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。